Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
---|---|---|---|
1 |
Material Type: Article
|
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trialThe Lancet, 2020-12, Vol.396 (10267), p.1979-1993 [Peer Reviewed Journal]2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license ;Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. Published by Elsevier Ltd.. All rights reserved. ;2020. Not withstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at http://creativecommons.org/licenses/by-nc-nd/4.0 ;2020. The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. This work is published under http://creativecommons.org/licenses/by-nc-nd/3.0/ (theLicense”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license 2020 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(20)32466-1 ;PMID: 33220855Digital Resources/Online E-Resources |
|
2 |
Material Type: Article
|
Acute lymphoblastic leukaemiaThe Lancet (British edition), 2020-04, Vol.395 (10230), p.1146-1162 [Peer Reviewed Journal]2020 Elsevier Ltd ;Copyright © 2020 Elsevier Ltd. All rights reserved. ;2020. Elsevier Ltd ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(19)33018-1 ;PMID: 32247396Full text available |
|
3 |
Material Type: Article
|
A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (FLAIR): a multicentre, randomised, crossover trialThe Lancet (British edition), 2021-01, Vol.397 (10270), p.208-219 [Peer Reviewed Journal]2021 Elsevier Ltd ;Copyright © 2021 Elsevier Ltd. All rights reserved. ;2021. Elsevier Ltd ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(20)32514-9 ;PMID: 33453783Full text available |
|
4 |
Material Type: Article
|
Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort studyThe Lancet (British edition), 2018-08, Vol.392 (10146), p.477-486 [Peer Reviewed Journal]2018 Elsevier Ltd ;Copyright © 2018 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Aug 11, 2018 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(18)31506-X ;PMID: 30129464Full text available |
|
5 |
Material Type: Article
|
Global, regional, and national age-sex-specific mortality and life expectancy, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017Lancet, 2018-11, Vol.392 (10159), p.1684-1735 [Peer Reviewed Journal]2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license ;Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. ;2018. The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. ;info:eu-repo/semantics/openAccess ;2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license (https://creativecommons.org/licenses/by/4.0/). https://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess ;2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license 2018 ;ISSN: 0140-6736 ;ISSN: 1474-547X ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(18)31891-9 ;PMID: 30496102Full text available |
|
6 |
Material Type: Article
|
Trajectories of childhood adversity and mortality in early adulthood: a population-based cohort studyThe Lancet (British edition), 2020-08, Vol.396 (10249), p.489-497 [Peer Reviewed Journal]2020 Elsevier Ltd ;Copyright © 2020 Elsevier Ltd. All rights reserved. ;2020. Elsevier Ltd ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(20)30621-8 ;PMID: 32798491Full text available |
|
7 |
Material Type: Article
|
The 21st century hazards of smoking and benefits of stopping: a prospective study of one million women in the UKThe Lancet (British edition), 2013-01, Vol.381 (9861), p.133-141 [Peer Reviewed Journal]Elsevier Ltd ;2013 Elsevier Ltd ;2015 INIST-CNRS ;Copyright © 2013 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Jan 12, 2013 ;2013 Elsevier Ltd. All rights reserved. 2013 Elsevier Ltd ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(12)61720-6 ;PMID: 23107252 ;CODEN: LANCAOFull text available |
|
8 |
Material Type: Article
|
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trialThe Lancet (British edition), 2012-11, Vol.380 (9856), p.1819-1828 [Peer Reviewed Journal]Elsevier Ltd ;2012 Elsevier Ltd ;2015 INIST-CNRS ;Copyright © 2012 Elsevier Ltd. All rights reserved. ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(12)61769-3 ;PMID: 23122652 ;CODEN: LANCAOFull text available |
|
9 |
Material Type: Article
|
Tobacco use in 3 billion individuals from 16 countries: an analysis of nationally representative cross-sectional household surveysThe Lancet (British edition), 2012-08, Vol.380 (9842), p.668-679 [Peer Reviewed Journal]Elsevier Ltd ;2012 Elsevier Ltd ;2015 INIST-CNRS ;Copyright © 2012 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Aug 18-Aug 24, 2012 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(12)61085-X ;PMID: 22901888 ;CODEN: LANCAOFull text available |
|
10 |
Material Type: Article
|
Physical activity behaviours in adolescence: current evidence and opportunities for interventionThe Lancet (British edition), 2021-07, Vol.398 (10298), p.429-442 [Peer Reviewed Journal]2021 World Health Organization. Published by Elsevier Ltd/Inc/BV. All rights reserved. ;Copyright © 2021 World Health Organization. Published by Elsevier Ltd/Inc/BV. All rights reserved. Published by Elsevier Ltd.. All rights reserved. ;2021. World Health Organization. Published by Elsevier Ltd/Inc/BV. All rights reserved. ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(21)01259-9 ;PMID: 34302767Full text available |
|
11 |
Material Type: Article
|
Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort studyThe Lancet, 2020-06, Vol.395 (10239), p.1763-1770 [Peer Reviewed Journal]2020 Elsevier Ltd ;Copyright © 2020 Elsevier Ltd. All rights reserved. ;2020. Not withstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at https://www.elsevier.com/legal/elsevier-website-terms-and-conditions ;2020. Elsevier Ltd ;2020 Elsevier Ltd. All rights reserved. 2020 Elsevier Ltd ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(20)31189-2 ;PMID: 32442528Digital Resources/Online E-Resources |
|
12 |
Material Type: Article
|
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trialThe Lancet, 2020-06, Vol.395 (10240), p.1845-1854 [Peer Reviewed Journal]2020 Elsevier Ltd ;Copyright © 2020 Elsevier Ltd. All rights reserved. ;2020. Not withstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at https://www.elsevier.com/legal/elsevier-website-terms-and-conditions ;2020. Elsevier Ltd ;2020 Elsevier Ltd. All rights reserved. 2020 Elsevier Ltd ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(20)31208-3 ;PMID: 32450106Digital Resources/Online E-Resources |
|
13 |
Material Type: Article
|
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trialThe Lancet, 2020-08, Vol.396 (10249), p.479-488 [Peer Reviewed Journal]2020 Elsevier Ltd ;Copyright © 2020 Elsevier Ltd. All rights reserved. ;2020. Not withstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at https://www.elsevier.com/legal/elsevier-website-terms-and-conditions ;2020. Elsevier Ltd ;2020 Elsevier Ltd. All rights reserved. 2020 Elsevier Ltd ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(20)31605-6 ;PMID: 32702299Digital Resources/Online E-Resources |
|
14 |
Material Type: Article
|
Irbesartan in Marfan syndrome (AIMS): a double-blind, placebo-controlled randomised trialThe Lancet (British edition), 2019-12, Vol.394 (10216), p.2263-2270 [Peer Reviewed Journal]2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license ;Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. ;2019. The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. This work is published under https://creativecommons.org/licenses/by/3.0/ (theLicense”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license 2019 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(19)32518-8 ;PMID: 31836196Full text available |
|
15 |
Material Type: Article
|
Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from RussiaThe Lancet, 2020-09, Vol.396 (10255), p.887-897 [Peer Reviewed Journal]2020 Elsevier Ltd ;Copyright © 2020 Elsevier Ltd. All rights reserved. ;2020. Not withstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at https://www.elsevier.com/legal/elsevier-website-terms-and-conditions ;2020. Elsevier Ltd ;2020 Elsevier Ltd. All rights reserved. 2020 Elsevier Ltd ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(20)31866-3 ;PMID: 32896291Digital Resources/Online E-Resources |
|
16 |
Material Type: Article
|
Body-mass index and obesity in urban and rural China: findings from consecutive nationally representative surveys during 2004–18The Lancet (British edition), 2021-07, Vol.398 (10294), p.53-63 [Peer Reviewed Journal]2021 Elsevier Ltd ;Copyright © 2021 Elsevier Ltd. All rights reserved. ;2021. Elsevier Ltd ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(21)00798-4 ;PMID: 34217401Full text available |
|
17 |
Material Type: Article
|
Global pattern of experienced and anticipated discrimination reported by people with major depressive disorder: a cross-sectional surveyThe Lancet (British edition), 2013-01, Vol.381 (9860), p.55-62 [Peer Reviewed Journal]Elsevier Ltd ;2013 Elsevier Ltd ;2015 INIST-CNRS ;Copyright © 2013 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Jan 5, 2013 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(12)61379-8 ;PMID: 23083627 ;CODEN: LANCAOFull text available |
|
18 |
Material Type: Article
|
Police killings and their spillover effects on the mental health of black Americans: a population-based, quasi-experimental studyThe Lancet (British edition), 2018-07, Vol.392 (10144), p.302-310 [Peer Reviewed Journal]2018 Elsevier Ltd ;Copyright © 2018 Elsevier Ltd. All rights reserved. ;2018. Elsevier Ltd ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(18)31130-9 ;PMID: 29937193Full text available |
|
19 |
Material Type: Article
|
Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional studyThe Lancet, 2020-10, Vol.396 (10259), p.1335-1344 [Peer Reviewed Journal]2020 Elsevier Ltd ;Copyright © 2020 Elsevier Ltd. All rights reserved. ;2020. Not withstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at https://www.elsevier.com/legal/elsevier-website-terms-and-conditions ;2020. Elsevier Ltd ;2020 Elsevier Ltd. All rights reserved. 2020 Elsevier Ltd ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(20)32009-2 ;PMID: 32987007Digital Resources/Online E-Resources |
|
20 |
Material Type: Article
|
The safety, immunogenicity, and acceptability of inactivated influenza vaccine delivered by microneedle patch (TIV-MNP 2015): a randomised, partly blinded, placebo-controlled, phase 1 trialThe Lancet (British edition), 2017-08, Vol.390 (10095), p.649-658 [Peer Reviewed Journal]2017 Elsevier Ltd ;Copyright © 2017 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Aug 12, 2017 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(17)30575-5 ;PMID: 28666680Full text available |